ÂÜÀòÂÒÂ×

Dr. Antoine Yver serves as Chairman of Development at Centessa Pharmaceuticals, Ltd. and also as an independent Director of the Board at Sanofi. Previously, Dr. Antoine Yver served as Executive Vice President, President and Global Head of Oncology R&D, and Chair of the Cancer Enterprise at Daiichi Sankyo, where his strategic leadership transformed Daiichi Sankyo from a small-molecule metabolic and cardiovascular drugmaker to an oncology biologics company.

Dr. Yver was the vision leader for Daiichi Sankyo’s global development of oncology pipeline and his leadership was fundamental for the practice-changing success of ENHERTU®. Prior to Daiichi, he was Senior Vice President at AstraZeneca, where he led the development of the global oncology pipeline and successfully launched 11 different drug products including TAGRISSO® and LYNPARZA®. In addition, he held various clinical development roles at Johnson & Johnson, Schering-Plough, Aventis Group and Rhone-Poulenc Rorer.

Dr. Antoine Yver has more than 25 years of oncology development and clinical experience. Dr. Yver is a pediatric oncologist and holds an M.D. from Université Paris-Saclay. He obtained a Master's degree in Immunology from the University of Paris. He completed his medical training at the Hôpitaux de Paris (AIHP).